State Key Laboratory of Medical Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, China.
School of Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Adv Sci (Weinh). 2024 Oct;11(40):e2402639. doi: 10.1002/advs.202402639. Epub 2024 Aug 29.
Host immunity is central to the virus's spread dynamics, which is significantly influenced by vaccination and prior infection experiences. In this work, we analyzed the co-evolution of SARS-CoV-2 mutation, angiotensin-converting enzyme 2 (ACE2) receptor binding, and neutralizing antibody (NAb) responses across various variants in 822 human and mice vaccinated with different non-Omicron and Omicron vaccines is analyzed. The link between vaccine efficacy and vaccine type, dosing, and post-vaccination duration is revealed. The classification of immune protection against non-Omicron and Omicron variants is co-evolved with genetic mutations and vaccination. Additionally, a model, the Prevalence Score (P-Score) is introduced, which surpasses previous algorithm-based models in predicting the potential prevalence of new variants in vaccinated populations. The hybrid vaccination combining the wild-type (WT) inactivated vaccine with the Omicron BA.4/5 mRNA vaccine may provide broad protection against both non-Omicron variants and Omicron variants, albeit with EG.5.1 still posing a risk. In conclusion, these findings enhance understanding of population immunity variations and provide valuable insights for future vaccine development and public health strategies.
宿主免疫是病毒传播动态的核心，这受到疫苗接种和先前感染经历的显著影响。在这项工作中，我们分析了 822 例接种了不同非奥密克戎和奥密克戎疫苗的人类和小鼠中，SARS-CoV-2 突变、血管紧张素转换酶 2（ACE2）受体结合和中和抗体（NAb）反应在各种变体中的共同进化。揭示了疫苗效力与疫苗类型、剂量和接种后持续时间之间的联系。对非奥密克戎和奥密克戎变体的免疫保护分类与遗传突变和疫苗接种共同进化。此外，引入了一种模型，即流行率评分（P-Score），该模型在预测接种人群中新变体的潜在流行率方面优于以前基于算法的模型。结合野生型（WT）灭活疫苗和奥密克戎 BA.4/5 mRNA 疫苗的混合疫苗接种可能对非奥密克戎变体和奥密克戎变体提供广泛的保护，尽管 EG.5.1 仍然存在风险。总之，这些发现增强了对人群免疫变异的理解，并为未来的疫苗开发和公共卫生策略提供了有价值的见解。
